TG Therapeutics, Inc. (TGTX)

NASDAQ

$31.42

+$0.07 (0.22%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$31.00$31.85

Open $31.38

52 Week Range

$25.28$46.48

Previous Close $31.35

Market Cap5.00B

Volume1.03M

Avg Volume1.85M

P/E (TTM)76.09

EPS (TTM)$0.41

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for TG Therapeutics, Inc.

NOV282025

TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Source: GlobeNewsWire•18 days ago

NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the 8th Annual Evercore Healthcare Conference, which is ta...

OCT312025

TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update

Source: GlobeNewsWire•46 days ago

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, November 3, 2025, at 8:30 AM ET to discuss results for the third quarter of 2025 and provide a business out...

OCT282025

TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI

Source: GlobeNewsWire•49 days ago

NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated Day 1 and Day 15 dosing schedule for IV BR...

SEP242025

New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment

Source: GlobeNewsWire•83 days ago

During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment...